IL-4–, TGF-β–, and IL-1–Dependent Expansion of Parasite Antigen-Specific Th9 Cells Is Associated with Clinical Pathology in Human Lymphatic Filariasis


J Immunol 2013; 191:2466-2473; Prepublished online 2 August 2013;
doi: 10.4049/jimmunol.1300911
http://www.jimmunol.org/content/191/5/2466

Why The JI?
• Rapid Reviews! 30 days* from submission to initial decision
• No Triage! Every submission reviewed by practicing scientists
• Speedy Publication! 4 weeks from acceptance to publication
*average

References This article cites 35 articles, 6 of which you can access for free at:
http://www.jimmunol.org/content/191/5/2466.full#ref-list-1

Subscription Information about subscribing to The Journal of Immunology is online at:
http://jimmunol.org/subscription

Permissions Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
IL-4–, TGF-β–, and IL-1–Dependent Expansion of Parasite Antigen-Specific Th9 Cells Is Associated with Clinical Pathology in Human Lymphatic Filariasis

Rajamanickam Anuradha,* Parakkal Jovvian George,* Luke E. Hanna,† Vedachalam Chandrasekaran,‡ Paul Kumaran,‡ Thomas B. Nutman,‡ and Subash Babu*‡

Th9 cells are a subset of CD4+ T cells, shown to be important in allergy, autoimmunity, and antitumor responses; however, their role in human infectious diseases has not been explored in detail. We identified a population of IL-9- and IL-10 coexpressing cells (lacking IL-4 expression) in normal individuals. These cells respond to antigenic and mitogenic stimulation, but are distinct from IL-9+ Th2 cells. We also demonstrate that these Th9 cells exhibit Ag-specific expansion in a chronic helminth infection (lymphatic filariasis). Comparison of Th9 responses reveals that individuals with pathology associated with filarial infection exhibit significantly expanded frequencies of filarial Ag-induced Th9 cells, but not of IL9+Th2 cells in comparison with filarial-infected individuals without associated disease. Moreover, the per cell production of IL-9 is significantly higher in Th9 cells compared with IL9+Th2 cells, indicating that the Th9 cells are the predominant CD4+ T cell subset producing IL-9 in the context of human infection. This expansion was reflected in elevated Ag-stimulated IL-9 cytokine levels in whole blood culture supernatants. Finally, the frequencies of Th9 cells correlated positively with the severity of lymphedema (and presumed inflammation) in filarial-diseased individuals. This expansion of Th9 cells was dependent on IL-4, TGF-β, and IL-1 in vitro. We have therefore identified an important human CD4+ T cell subpopulation coexpressing IL-9 and IL-10, but not IL-4, the expansion of which is associated with disease in chronic lymphatic filariasis and could potentially have an important role in the pathogenesis of other inflammatory disorders. The Journal of Immunology, 2013, 191: 2466–2473.

Traditionally associated with the Th2 response, IL-9 is a member of the common γ-chain cytokine family and exerts broad effects on many cell types, including mast cells, eosinophils, T cells, and epithelial cells (1, 2). However, it has become apparent from studies in mice that many different CD4+ T cell subsets have the capacity to secrete IL-9. A subset of IL-9–producing CD4+ T cells (Th9 cells) distinct from Th1, Th2, and Th17 cells has been identified (3, 4). These Th9 cells are characterized by the coincident production of IL-9 and IL-10 and develop from naive CD4+ T cells under the combined influence of IL-4 and TGF-β (3, 4). It has also been shown that IL-9 secretion of murine Th2 cells is also dependent on TGF-β and that TGF-β can redirect committed Th2 cells toward the Th9 phenotype (4). IL-1 family members can also contribute to IL-9 production (5). Moreover, regulatory T cells expressing IL-9 have been described as having a role in the induction of peripheral tolerance (6). Finally, murine Th17 cells have also been shown to secrete significant amounts of IL-9 (7). Few studies have examined the role of Th9 cells in humans. Th9 cells in humans were initially described as IL-9 cells coexpressing IL-17 (8); however, IL-9–producing CD4+ T cells distinct from Th1, Th2, and Th17 cells have also been described recently (9, 10). In humans, Th9 cells are thought to play an important role in allergy (11), atopy (12), asthma (11), autoimmunity (13), and antitumor immunity (14). Although IL-9 has been implicated in resistance to intestinal helminth infection (15, 16), the role of IL-9 in human parasitic infections is not known. Moreover, data on the role of Th9 cells in any infectious disease are scant.

Lymphatic filariasis is a parasitic disease caused by nematode worms that can manifest in a variety of clinical and subclinical conditions (17). The majority of the 120 million infected individuals are clinically asymptomatic, but a significant minority of individuals (~40 million) are known to develop lymphatic pathology following infection. The most common pathologic manifestations of lymphatic filariasis are adenolymphangitis, hydrocele, and lymphedema (elephantiasis in its most severe form) (17). The pathogenesis of lymphatic filarial disease is thought to be associated with the expansion of Ag-responsive Th1 and Th7 cells (18, 19).

Th9 cells have been shown to act as mediators of inflammation in experimental disease models, such as collitis, peripheral neuritis and experimental autoimmune encephalitis (3, 7, 20); however, IL-9 has also been shown to participate in peripheral tolerance by increasing the survival and activity of regulatory T cells (21). Therefore, it is still unclear whether IL-9 mediates proinflammatory or anti-inflammatory activity. Because filarial infection exhibits differences in clinical manifestations with both an inflammatory component (filarial disease) and a noninflammatory component (asymptomatic infection), we postulated that this infection would...
provide an ideal milieu to examine the role of Th9 cells in inflammation and infection.

We first identified a population of IL-9 and IL-10 coexpressing CD4+ T cells (Th9 cells) that can be distinguished from IL-9+ Th2 cells and demonstrate their expansion in response to both cognate Ag and mitogen stimulation. We next demonstrated that this Th9 population was expanded in filarial disease (lymphedema), and their frequencies were directly related to the severity of disease. Moreover, this expansion appears to be critically dependent IL-4, TGF-β, and IL-1.

Materials and Methods

Study population

We first studied a group of 15 normal (NL) individuals. We later expanded the study to include 47 individuals with filarial lymphedema (hereafter CP) and 39 clinically asymptomatic, filarial-infected (hereafter INF) individuals in an area endemic for LF in Tamil Nadu, South India (Table I). All NL individuals were circulating filarial Ag negative and had no signs or symptoms of infection or disease. All CP individuals were circulating filarial Ag negative by both the immunochromatographic test (ICT) filarial Ag test (Binax, Portland, ME) and the TropBio Og4C3 ELISA (Trop Bio Pty. Ltd, Townsville, Queensland, Australia), indicating a lack of current active infection. The diagnosis of prior filarial infection was made by history and clinical examination as well as positive Brugia malayi Ag (BmA)–specific IgG4, BmA-specific IgG4 and IgG ELISA were performed exactly as described previously (22). The illness of each CP individual was classified according to the standard four grades established by the World Health Organization: grade one, pitting edema that is not reversible by elevation of the affected limb; grade two, pitting or nonpitting edema that is not reversible by elevation of affected limb; grade three, nonpitting edema that is not reversible by elevation of the affected limb and that is accompanied by thickening of the skin; grade four, nonpitting edema of the limb that is accompanied by fibrotic and verrucous skin changes (elephantiasis). All INF individuals had a positive test result for active infection by both the ICT filarial Ag test and the TropBio Og4C3 ELISA and had not received any antifilarial treatment before this study. There were no differences between the groups in terms of demographics or socioeconomic status. All individuals were examined as part of clinical protocols approved by institutional review boards of both the National Institutes of Allergy and Infectious Diseases and the National Institute for Research in Tuberculosis (NCT00375583 and NCT00001230), and informed written consent was obtained from all participants.

Parasite and control Ag

Saline extracts of B. malayi adult worms (BmA) and microfilariae (MI) were used for parasite Ags and mycobacterial purified protein derivative (PPD; Serum Statens Institute, Copenhagen, Denmark) was used as the control Ag. Final concentrations were 10 μg/ml for BmA, MI, and PPD. Endotoxin levels in the BmA was <0.1 EU/ml using the QCL-1000 Chromogenic LAL test kit (BioWhittaker). PMA and ionomycin at concentrations of 12.5 ng/ml and 125 ng/ml (respectively), were used as the positive control stimuli.

In vitro culture

Whole blood cell cultures were performed to determine the frequencies of cytokine-producing CD4+ T cells (CP = 23; INF = 25; UN = 15). Whole blood was diluted 1:1 with RPMI 1640 medium, supplemented with penicillin/streptomycin (100 U/100 μg/ml), l-glutamine (2 mM), and HEPES (10 mM; all from Invitrogen, San Diego, CA) and placed in 12-well tissue culture plates (Costar, Corning, NY). The cultures were then stimulated with BmA, MI, PPD, PMA/ionomycin (P/I), or media alone in the presence of the costimulatory reagent, CD49d/CD28 (BD Biosciences) at 37 °C for 6 h. FastImmune Brefeldin A Solution (10 μg/ml; BD Biosciences) was added after 2 h. After 6 h, whole blood was centrifuged and washed with cold PBS, and 1× FACS lysing solution (BD Biosciences) was used. The cells were fixed using Cytofix/Cytoperm buffer (BD Biosciences), cryopreserved, and stored at −80 °C until use. For cytokine neutralization experiments, whole blood from a separate set of CP (n = 10) individuals was cultured in the presence of anti–IL-4 (5 μg/ml), anti–TGF-β (5 μg/ml), anti–IL-1R (2.5 μg/ml), anti–IL-6R (2.5 μg/ml), or isotype control Ab (5 μg/ml; R&D Systems) for 18 h, after which BmA was added and cultured for an additional 6 h.

Intracellular cytokine staining

The cells were thawed and washed with PBS, washed later with PBS/1% BSA, and stained with surface Abs for 30–60 min. Surface Abs used were CD3 AmCyan, CD4 APC-H7, and CD8 PE-Cy7 (all from BD Biosciences). The cells were washed and permeabilized with BD Perm/Wash buffer (BD Biosciences) and stained with intracellular cytokines for an additional 30 min before washing and acquisition. Cytokine Abs were IL-4 FITC and IL-10 APC (BD Pharmingen) and IL-9 PE (eBiosciences). Flow cytometry was performed on a FACS Canto II flow cytometer with FACSDiva software version 6 (Becton Dickinson). The lymphocyte gating was set by forward and side scatter, and 100,000 gated lymphocyte events were acquired. Data were collected and analyzed using FlowJo software. All data are depicted as frequency of CD4+ T cells expressing cytokines or as the mean fluorescence intensity (MFI) of cytokine expression within a particular subset. Values following media stimulation are depicted as baseline frequency, whereas frequencies following stimulation with Ags or P/I are depicted as net frequencies (with baseline values subtracted).

ELISA

Whole blood cell cultures were also performed to measure IL-9 production. Whole blood from a separate set of CP (n = 14) and INF (n = 14) individuals was cultured in 12-well tissue culture plates for 72 h in the presence of BmA or PPD, and culture supernatants were collected. IL-9 ELISA (eBiosciences) was performed according to the manufacturer’s instructions.

Statistical analysis

Data analyses were performed using GraphPad PRISM (GraphPad Software, San Diego, CA). Geometric means (GM) were used for measurements of central tendency. Statistically significant differences between the groups were analyzed by using the Mann–Whitney U test followed by Holm’s correction for multiple comparisons, and differences within the same group were determined using the Wilcoxon signed rank test. Correlation analysis was performed using Spearman rank test.

Results

Identification of IL-9 and IL-10 coexpressing cells and their expansion following PPD and PMA/I stimulation

To determine whether Th9 cells (defined as IL-9+, IL-10+, and IL-4+) are present in normal individuals, we measured the frequency of these cells in a group of NL individuals at baseline and following stimulation with a standard Ag (PPD) and a mitogenic stimulus (PMA/I). As shown in a representative contour plot (Fig. 1A), we were able to detect Th9 cells coexpressing IL-9 and IL-10 in normal individuals. As shown in Fig. 1B, this population exhibits significant expansion in response to PPD (3-fold) and PMA/I (8.5-fold) stimulation. IL-9 expression on CD4+ T cells was also detected in Th2 cells (expressing IL-9 and IL-4), and a similar expansion was observed following PPD (2.5-fold) and PMA/I (25.5-fold) stimulation (Fig. 1C). Thus, Th9 cells, similar to their murine counterparts, are responsive to Ag and mitogen.

Increased frequencies of filarial Ag-stimulated Th9 cells and elevated IL-9 production in filarial lymphedema

To determine the expression of Th9 cells in an infectious disease with an inflammatory component, we measured the frequency of Th9 cells in CP and compared them to INF individuals (Table I). As shown in Fig. 2A, whereas parasite-Ag (BmA) induces expansion of Th9 cells in both CP and INF individuals, CP individuals exhibited a significantly greater expansion of classical Th9 cells (IL-9+, IL-10+, IL-4+) in response to BmA (1.8-fold) compared with INF individuals. In addition, the per cell expression of IL-9 expression (based on MFI) on Th9 cells was also significantly increased after BmA stimulation in both groups, but this enhancement was significantly greater (1.3-fold) in CP compared with INF individuals. Similarly, as shown in Fig. 2B, both the frequencies of Th9 cells (2-fold) as well as the MFI of IL-9 expression (1.2-fold) on these cells was significantly higher in CP compared with INF individuals in response to a second filarial Ag—Mf. In addition, CP individuals did not exhibit any significant
difference in the frequency of Th9 cells in response to PPD or PMA/I compared with INF individuals (data not shown). Moreover, filarial Ag-induced net frequencies of Th9 cells were significantly higher in CP compared with NL, uninfected individuals as well (data not shown), indicating that heightened expansion of Th9 cells is specific to individuals with pathology. Finally, as shown in Fig. 2C, CP individuals exhibit significantly elevated production of IL-9 in whole blood supernatants in response to BmA (GM of 11.7 pg/ml in CP versus 6.4 in INF) but not PPD (data not shown) in a comparison with INF individuals. Thus, filarial lymphatic disease is associated with enhanced Ag-driven frequencies of Th9 cells and increased production of IL-9, both on a per cell basis and in bulk populations.

Decreased frequencies of filarial Ag-stimulated Th2 cells expressing IL-9 in filarial lymphedema

Because IL-9 is also expressed by conventional Th2 cells, we measured and compared the frequency of IL-9+Th2 cells in CP and

---

**Table I. Characteristics of the study population**

<table>
<thead>
<tr>
<th>Demographic</th>
<th>CP (n = 47)</th>
<th>INF (n = 39)</th>
<th>NL (n = 15)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age in years (range)</td>
<td>44 (29–65)</td>
<td>39 (23–65)</td>
<td>36 (24–65)</td>
</tr>
<tr>
<td>Sex (male/female)</td>
<td>33 / 14</td>
<td>29 / 10</td>
<td>9 / 6</td>
</tr>
<tr>
<td>Lymphedema, elephantiasis</td>
<td>Yes</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>ICT card test result</td>
<td>Negative</td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td><em>Wuchereria bancrofti</em> circulating Ag levels (U/ml) [GM (Range)]</td>
<td>&lt; 32&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1409 (138–22377)</td>
<td>&lt;32</td>
</tr>
</tbody>
</table>

<sup>a</sup>Below the limits of detection.
INF individuals. As shown in Fig. 3A, parasite Ag (BmA) induces expansion of Th2 cells expressing IL-9 and IL-10 but not IL-4 (classical Th9 cells) in CP (n = 23) and INF (n = 25) individuals and the MFI of IL-9 expression on Th9 cells. (B) Filarial Ag (Mf) induced frequencies of CD4+ T cells expressing IL-9 and IL-10 but not IL-4 (classical Th9 cells) in CP (n = 23) and INF (n = 25) individuals and the MFI of IL-9 expression on Th9 cells. (C) Filarial Ag (BmA) induced total levels of IL-9 whole blood culture supernatants in CP (n = 14) and INF (n = 14) individuals. The data are represented as frequencies and MFI of CD4+ T cells or levels of cytokine in the supernatants, and each line represents a single individual; p values were calculated using the Wilcoxon signed rank test and the Mann–Whitney U test.

FIGURE 2. Filarial lymphedema is associated with elevated frequencies of filarial Ag-induced classical Th9 cells with increased IL-9 production. (A) Filarial Ag (BmA) induced frequencies of CD4+ T cells expressing IL-9 and IL-10 but not IL-4 (classical Th9 cells) in CP (n = 23) and INF (n = 25) individuals and the MFI of IL-9 expression on Th9 cells. (B) Filarial Ag (Mf) induced frequencies of CD4+ T cells expressing IL-9 and IL-10 but not IL-4 (classical Th9 cells) in CP (n = 23) and INF (n = 25) individuals and the MFI of IL-9 expression on Th9 cells. (C) Filarial Ag (BmA) induced total levels of IL-9 whole blood culture supernatants in CP (n = 14) and INF (n = 14) individuals. The data are represented as frequencies and MFI of CD4+ T cells or levels of cytokine in the supernatants, and each line represents a single individual; p values were calculated using the Wilcoxon signed rank test and the Mann–Whitney U test.
driven frequencies of IL-9+Th2 cells expressing IL-9, suggesting that Th2 cells are not associated with pathology in filarial infections even if they coexpress IL-9.

Positive relationship between the frequency of classical Th9 cells and the grade of pathology in filarial lymphedema

To determine the relationship between Th9 cells and IL-9+Th2 cells with the severity of filarial disease, we measured the frequencies of Th9 cells and IL-9+Th2 and related them to the grade of lymphedema (according to the World Health Organization classification) in the CP individuals. As shown in Fig. 4A, we observed a significant positive correlation of Th9 cells at baseline (r = 0.81; p < 0.0001) and following BmA (r = 0.62; p = 0.0014) or Mf (r = 0.92; p < 0.0001) stimulation with the grade of lymphedema in these individuals. In contrast (Fig. 4B), we observed no relationship between IL-9+Th2 cells expressing IL-9 at baseline (r = 0.016) and following BmA (r = 0.104) or Mf (r = 0.107) stimulation with the grade of lymphedema in CP individuals. We also observed a significant correlation between baseline or Ag-induced IL-9 levels in whole blood supernatants with the degree of pathology (data not shown). Thus, we provide corroborative evidence for a potential role for Th9 cells in filarial disease pathogenesis.

Blockade or IL-4, TGF-β, and IL-1R but not IL-6R results in significantly decreased expansion of Th9 cells

IL-4 and TGFβ are known to be predominant cytokines inducing the generation of Th9 cells in murine systems; therefore, we investigated the role of IL-4 and TGF-β in modulating the frequency of Th9 cells. In addition, we also wanted to explore the role of IL-1 and IL-6, two cytokines known to have active roles in Th17 differentiation (23). To this end, we measured the frequency of Th9 cells and IL-9+Th2 cells in CP individuals (n = 10) following in vitro neutralization of IL-4 or TGF-β or IL-1R or IL-6R and stimulation with BmA. As shown in Fig. 5A, CP individuals exhibited significantly decreased net frequencies of Th9 cells (1.5-fold) after IL-4, TGF-β, and IL-1R blockade, but not after IL-6R blockade. Following cytokine blockade, only blockade of TGF-β and IL-1R (but not IL-4 and IL-6R) altered the frequencies of IL-9+Th2 cells (1.5-fold; Fig. 5B). Similar blockade of IL-4, TGF-β, and IL-1 signaling resulted in diminished frequencies of Th9 cells in response to PPD in normal individuals (data not shown). Thus, IL-4, TGF-β, and IL-1 all have roles in regulating the expansion of Th9 cells in vitro.

Discussion

Th9 cells are a recently discovered subset of CD4+ T cells, characterized by their unique ability to produce both IL-9 and IL-10 but not IL-4 (24, 25). The latter is considered to be the main distinguishing feature of Th9 cells, because classical Th2 cells can also produce IL-9. In addition, innate lymphoid cells are commonly present at mucosal barriers and are major producers of IL-9 (2). Th9 cells are characteristic induced by IL-4 and TGF-β (3, 4) and express the transcription factors PU.1 and IFN regulatory factor 4 (26, 27). Th9 cells are important contributors to allergic inflammation, and Th9 cells differentiated from atopic patients secrete more IL-9 than those from nonatopic patients do (12). Furthermore, allergic donors have substantially increased frequencies of Th9 cells compared with nonallergic donors (9). Th9 cells have also been shown to be present at increased frequencies in malignant pleural effusions (28) and in normal skin and blood
of patients with malignant melanoma (14). Thus, although Th9 cells are known to be involved in asthma (29), allergy (11), and antitumor responses (14, 30), the role of this CD4+ T subset in infectious diseases is not well characterized. Th9 cells are induced in pulmonary tuberculosis (31), but their role in host defense is not known. IL-9 is also associated with certain Th2 cell–mediated responses, including mucus production from intestinal goblet cells and lung epithelial cells, as well as intestinal and pulmonary mastocytosis (15, 32). Mice with systemic overexpression of IL-9 develop intestinal mastocytosis and enhanced production of serum IgE, and they are resistant to intestinal infection by the helminth parasite *Trichuris muris* (15). In addition, IL-9 blockade prevents worm expulsion and blood eosinophilia in mice infected with the same helminth (16).

Our study reveals certain interesting features of IL-9–producing CD4+ T cells in humans. First, by using multiparameter flow cytometry and intracellular cytokine staining, we demonstrate the presence of a CD4+ T cell subset expressing both IL-9 and IL-10 but not IL-4, which we designated as Th9 cells because this subset resembles the Th9 cells described in mice. Second, we demonstrate that IL-9 is also produced by a different subset of CD4+ T cells that also express IL-4 but not IL-10 and are by definition Th2 cells. Third, we demonstrate that both these CD4+ T cell subsets expand in frequency following stimulation with a common Ag and polyclonal stimulation. The relative frequencies of Th9 cells as detected in our study are rather low, but this is not different from ex vivo frequencies of these cells observed in other studies (8, 9). To our knowledge, this study is the first in humans to characterize this precise CD4+ helper T cell subset in helminth infections.

Lymphatic filariasis is characterized by a diverse set of clinical manifestations, including an asymptomatic (or subclinical) form seen among the majority of infected people (33). Although adaptive immune responses, especially T cell responses, are clearly important in the progression of asymptomatic infection to overt filarial disease, the nature of these T cell responses is still poorly characterized (17). Dysregulation of CD4+ T cell–mediated immune activation, however, can lead to the development of tissue inflammation and pathology. Expansion of (or lack of suppressed) Ag-driven Th1 type CD4+ T cells have long been considered the hallmark of chronic pathology in filariasis (17). More recently, the involvement of Th17 responses has also been implicated (19). Therefore, we sought to elucidate whether filarial-induced pathogenic reactions were associated with Th9 responses and to delineate the CD4+ T cell subsets expressing IL-9 in filarial infections (and in normal subjects). We examined the expression of IL-9 in CD4+ T cells in CP individuals and contrasted this with IL-9 expression in INF individuals. Th9 cells have been associated with the development of pathology during allergic inflammation and autoimmune disease (24, 25). We provide direct evidence for associations among Th9 cells, IL-9 production, and clinical pathology in the form of lymphedema and elephantiasis in filarial infections. Our data show that filarial pathology is characterized by
an expanded frequency of Th9 cells, but not IL-9+ Th2 cells expressing IL-9. In fact, Th2 cells coexpressing IL-9 exhibit greatly diminished Ag-driven frequencies in filarial pathology, suggesting that IL-9 expression alone is not a characteristic feature of filarial disease. Rather, the presence of Th9 cells (with their capacity to secrete significantly increased amounts of IL-9 as characterized by both IL-9 production in whole blood supernatants and the per cell production of Th9 cells following Ag stimulation) appears to be the more important cellular feature associated with pathogenesis. This observation is reinforced further by the positive correlation observed between the Th9 cell percentages and the grade of lymphedema, which essentially reflects the severity of filarial disease. Although the exact mechanism by which these Th9 cells potentially promote or exacerbate pathology remains to be determined, it is clear that filarial pathology is closely associated with the expansion of these cells and with elevated production of IL-9.

Although IL-4 and TGF-β have been described as the main inducers of Th9 differentiation in the mouse (3, 4), few studies in humans have addressed the role of these cytokines in human Th9 differentiation (8, 34). Our study demonstrates a critical role for both IL-4 and TGF-β in driving the expansion of Th9 cells in filarial infections. Moreover, our data also reveal important clues regarding the regulation of Th9 cells versus Th2 cells coexpressing IL-9. IL-4 was found to be necessary for Th9 induction, but TGF-β was found to be necessary for the induction of both Th9 cells and Th2 cells coexpressing IL-9. Thus, we identify an important role for TGF-β in the expansion of IL-9–producing Th2 in filarial infections. IL-1 has been shown to be capable of inducing IL-9 expression under some conditions, but its role in the differentiation of Th9 cells remains unclear (8, 35). Moreover, IL-1 synergizes with IL-6 in inducing differentiation of Th17 cells in humans (23). Therefore, we also explored the role of IL-1 and IL-6 in the Ag-induced differentiation of Th9 cells in CP individuals. Interestingly, we found that IL-1 but not IL-6 was involved in the expansion of Th9 cells and in mediating the expression of IL-9 in Th2 cells. As a result, we have uncovered a novel cytokine pathway influencing the expansion and differentiation of Th9 cells and IL-9+Th2 cells involving the IL-1 family.

Our finding that Th9 responses are induced in patients with filarial pathology has clear implications. IL-9 has a major role in protection against and expulsion of intestinal helminths (15), but it also participates in the pathogenic processes of allergy and asthma (24, 25). Moreover, Th9 cells have been shown to promote pathogenic processes and induce pathology in several autoimmune disease models in mice (24, 25). The mechanism by which Th9 cells promote pathology is not known, although it is speculated to depend on the effect of IL-9 on promoting inflammatory responses in target cells, including epithelial cells and mast cells (2). Our
findings implicate a potential pathogenic role for Th9 cells in filarial disease. Our findings also suggest that strategies designed to block IL-9 or its downstream targets could potentially play a major role in amelioration of disease in lymphatic filariasis. In conclusion, we report an important association of Th9 cells with pathology in filarial infections and demonstrate a role for IL-4, TGF-β, and IL-1 in the regulation of this CD4+ T cell subset.

Acknowledgments

We thank the staff of the Filariasis Clinic, Government General Hospital (Chennai, India), especially Drs. M. Sathiswaran and R. Yegneshwaran, as well as the National Institute for Research in Tuberculosis Epidemiology Unit for assistance with patient recruitment.

Disclosures

The authors have no financial conflicts of interest.

References

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.

The authors have no financial conflicts of interest.